Thus, blocking CCR10 may be a useful approach for skin inflammatory diseases, idiopathic pulmonary fibrosis, and enhancing the efficacy of cancer therapies (20, 21). This evidence concerns the gene CCR10 and idiopathic pulmonary fibrosis.